Co-design of Guidance for Patient and Public Involvement in Psychedelic Research
James B. Close, Julia Bornemann, Maria Piggin, Sandra Jayacodi, Lisa Luan, Robin Carhart-Harris, Meg J. Spriggs
Frontiers in Psychiatry September 30, 2021 DOI: 10.3389/fpsyt.2021.727496 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Citations | 21 |
| Key points | Proposes that core values of trust, learning, purpose, and inclusivity are essential for patient and public involvement in psychedelic research, and presents co-designed guidance for planning such involvement. |
Abstract
Within the context of scientific research, patient and public involvement (PPI) is defined as research performed “with” or “by” patients and members of the public, rather than “to,” “about”, or “for” them. When carried out systematically and thoughtfully, PPI has the potential to strengthen the quality and impact of research by fostering accountability, transparency, and relevance. There exist numerous guidelines, frameworks and tools for supporting PPI, however, these do not account for the unique challenges faced in psychedelic research. This paper describes the co-design of guidance intended to help build, evaluate and improve PPI in psychedelic research. A steering group was formed to design and run a co-design workshop alongside public collaborators. Insights from this workshop were analyzed and refined into a comprehensive and readily usable guide for planning PPI specific to the field of psychedelic research. Core values emerging from the process focused on the essential importance of trust, learning, purpose and inclusivity. It is hoped that this guidance will be a starting point for incorporating PPI in future psychedelic research, so that it can grow and adapt as this burgeoning field of research progresses.
Citations in the library
Cited by 19
- Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression Frontiers in Pharmacology March 31, 2022
- Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study” Frontiers in Psychiatry October 20, 2021
- Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research Frontiers in Psychiatry November 12, 2021
- Development and psychometric validation of a novel scale for measuring 'psychedelic preparedness'. Scientific Reports February 8, 2024
- Development of a digital intervention for psychedelic preparation (DIPP). Scientific Reports February 19, 2024
and 14 more in the library
Cites 28
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
and 23 more in the library